Beijing Sun Novo Pharmaceutical Research Co Ltd

Beijing Sun Novo Pharmaceutical Research Co Ltd

688621 · SHG · Healthcare / Drug Manufacturers - Specialty & Generic

54.20CNY-0.64 (-1.17%)

Price History

Full chart

Market Stats

Previous Close54.84
Open54.89
Day Range53.84 – 55.75
52-Week Range46.51 – 80.40
Volume1.15M
Market Cap7.95B
P/E (TTM)154.35
Forward P/E0.00
EPS0.46
Dividend Yield0.26%
Beta-0.10
50-Day Avg67.27
200-Day Avg62.81

About

Beijing Sun-Novo Pharmaceutical Research Co., Ltd., a contract research company, engages in the research and development of drugs in China. The company operates an external preparation platform that focuses on the research and development of new drugs and generic drugs for skin external preparations; children's clinical data bridging research center; pediatric drug research and development platform; pediatric drug delivery dosage research and development platform; oncology, metabolic diseases, respiratory tract drug delivery and topical preparation platforms; polypeptide and other drug molecular design and development platform; genotoxic impurity detection platform; technology platform for slow and controlled release preparations; drug synthesis platform; and synthesis technology platform. It also offers SMO, clinical quality management, data management and statistical analysis, project management, test center, clinical research center, clinical trials, TMFDocument management, quality control, Medical Writing, medical monitoring, and pharmacovigilance services; and registration-related services for chemical drugs, biological products, and medical device products. In addition, the company operates a quantitative pharmacology platform that uses technology in pharmacokinetics, pharmacodynamics, body function, disease mechanism and test process, and other information for quantitative research; and mass spectrometry, immunological analysis, cell biology, and molecular biology platforms that provide biological analysis services for large and small molecular drugs, as well as operates as a Contract Research Organization for Professional Peptide Drug Research and Development. The company offers clinical research technology services to pharmaceutical companies and new drug research institutions. Beijing Sun-Novo Pharmaceutical Research Co., Ltd. was founded in 2009 and is based in Beijing, China.

Company Details

  • SectorHealthcare
  • IndustryDrug Manufacturers - Specialty & Generic
  • CEOMr. Yujing Liu
  • Employees1.10K
  • HeadquartersBuilding 7, Beijing, China, 102200, China
  • Websitehttps://www.sun-novo.com

Leadership

  • Mr. Yujing LiuGM & Director · b. 1982
  • Mr. Zhi Jiao ZhangFinance Director & Director · b. 1979
  • Mr. Huan LuoDeputy GM & Director · b. 1984
  • Ms. Li Ping WeiSecretary & Director · b. 1989
  • Ms. Yan ShaoDeputy General Manager · b. 1978
  • Mr. Guangtao HaoDeputy GM & Core Technician · b. 1980
  • Mr. Yuanbo LiDeputy General Manager · b. 1979
  • Hao ChenAccounting Supervisor
  • Ms. Ming Juan WangCore Technical Staff · b. 1976
  • Mr. Dao Sheng XieCore Technical Staff · b. 1985

Financials

Income Statement

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue36.05M134.80M233.53M347.36M493.65M676.61M932.12M1.08B1.22B
Growth (%)-+273.91%+73.24%+48.74%+42.12%+37.06%+37.76%+15.70%+12.92%
Cost of Revenue21.73M77.66M126.36M175.02M229.97M301.15M403.77M537.33M560.80M
Gross Profit14.32M57.13M107.17M172.33M263.68M375.46M528.35M541.14M1.22B
Gross Margin39.72%42.39%45.89%49.61%53.41%55.49%56.68%50.18%100.00%
Operating Expense13.17M33.50M52.13M89.55M141.09M206.18M334.19M363.45M1.01B
Operating Income1.15M23.63M55.04M82.78M122.59M169.27M194.16M177.69M204.20M
Operating Margin3.20%17.53%23.57%23.83%24.83%25.02%20.83%16.48%16.77%
EBITDA4.22M30.49M62.52M92.94M137.21M196.07M227.64M217.53M226.46M
EBITDA Margin11.71%22.62%26.77%26.76%27.80%28.98%24.42%20.17%18.60%
Net Income1.98M20.72M47.40M72.46M105.66M156.47M184.76M177.41M196.08M
Net Income Margin5.49%15.37%20.30%20.86%21.40%23.13%19.82%16.45%16.10%
R&D2.80M8.46M19.07M34.19M47.58M89.69M123.68M171.94M161.56M
R&D as % of Total Revenue7.78%6.28%8.16%9.84%9.64%13.26%13.27%15.94%13.27%
Interest Expense848.21K2.10M776.45K1.04M3.61M9.88M12.24M16.16M16.45M
Interest Expense % of Total Revenue2.35%1.56%0.33%0.30%0.73%1.46%1.31%1.50%1.35%

Balance Sheet

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets110.07M201.50M285.51M384.86M1.24B1.46B1.86B1.99B2.28B
Total Liabilities76.82M127.68M166.76M191.94M473.01M554.86M805.76M884.65M1.05B
Total Equity34.11M75.24M116.64M189.10M761.95M896.70M1.04B1.10B1.22B
Cash5.62M31.70M76.49M109.31M490.25M608.93M690.93M565.56M462.17M
Total Debt24.58M4.88M15.86M23.50M206.71M257.55M424.55M411.71M-
Net Debt18.96M-26.83M-60.63M-85.81M-283.54M-351.38M-244.28M-153.85M84.96M

Cash Flow

Currency: CNY2017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow8.01M44.11M56.97M62.99M88.25M103.96M92.86M32.02M93.21M
Investing Cash Flow-32.68M20.27M-15.16M-35.70M-275.78M-11.50M-88.66M-42.63M-
Financing Cash Flow21.12M-38.30M2.97M5.52M568.48M26.22M77.80M-127.74M-
Capital Expenditure20.96M16.41M25.67M27.03M84.96M103.87M72.96M30.48M42.43M
Free Cash Flow-12.94M27.70M31.30M35.96M3.29M91.92K19.90M1.54M50.78M
Dividends Paid507.50K1.06M306.24K1.07M1.25M21.20M55.52M38.15M32.26M
FCF to OCF-161.57%62.79%54.94%57.09%3.73%0.09%21.43%4.80%54.48%
Dividend Paid to FCF-3.92%3.83%0.98%2.98%37.88%23064.54%278.95%2484.39%63.53%

Earnings

Report DateAug 19, 2021Oct 27, 2021Jan 20, 2022Apr 28, 2022Aug 9, 2022Oct 24, 2022Feb 9, 2023Apr 27, 2023
EPS Estimate--------
EPS Actual0.950.440.260.420.670.520.340.43
Surprise--------
TimingAfter-hoursPre-marketPre-marketPre-marketPre-marketAfter-hoursPre-marketPre-market

Key Statistics & Ratios

Market Cap7.95B
Enterprise Value8.61B
Trailing P/E154.35
Forward P/E0.00
Price / Sales7.52
Price / Book7.02
EPS0.46
Book Value11.00
Revenue (TTM)1.06B
Gross Profit (TTM)566.31M
EBITDA44.91M
Profit Margin4.69%
Operating Margin-25.09%
Return on Equity4.54%
Return on Assets0.59%
Shares Outstanding112.00M
Shares Float71.14M
Beta-0.10
Dividend Yield0.26%
Dividend Rate0.19
Payout Ratio40.65%

Dividends

20261×
0.19Jun 29, 2026
20251×
0.16Jun 11, 2025
20241×
0.17Jul 9, 2024
20231×
0.60May 12, 2023
20221×
0.19Apr 15, 2022

Stock Splits

  • May 12, 20231.4:1